IRIS
BARGAGLI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.807
EU - Europa 26.784
AS - Asia 14.009
SA - Sud America 2.574
Continente sconosciuto - Info sul continente non disponibili 1.517
AF - Africa 764
OC - Oceania 58
AN - Antartide 1
Totale 76.514
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.047
IT - Italia 7.690
RU - Federazione Russa 5.240
SG - Singapore 4.359
CN - Cina 3.797
GB - Regno Unito 3.780
IE - Irlanda 3.000
BR - Brasile 2.088
VN - Vietnam 1.800
SE - Svezia 1.387
DE - Germania 1.372
FR - Francia 1.372
HK - Hong Kong 1.319
FI - Finlandia 825
UA - Ucraina 810
KR - Corea 566
IN - India 535
CA - Canada 418
BD - Bangladesh 393
ZA - Sudafrica 360
ES - Italia 275
NL - Olanda 269
JP - Giappone 192
IQ - Iraq 165
MX - Messico 156
PL - Polonia 156
TR - Turchia 147
AR - Argentina 142
CZ - Repubblica Ceca 112
AT - Austria 101
CI - Costa d'Avorio 96
NG - Nigeria 89
EC - Ecuador 84
PK - Pakistan 83
ID - Indonesia 74
UZ - Uzbekistan 64
CO - Colombia 63
BE - Belgio 62
SA - Arabia Saudita 61
VE - Venezuela 61
IR - Iran 55
MA - Marocco 50
PH - Filippine 50
KE - Kenya 48
AU - Australia 47
JM - Giamaica 41
CL - Cile 40
CH - Svizzera 39
AE - Emirati Arabi Uniti 38
LT - Lituania 35
JO - Giordania 34
EG - Egitto 32
PY - Paraguay 31
PT - Portogallo 30
AZ - Azerbaigian 29
MY - Malesia 29
PE - Perù 28
RO - Romania 26
IL - Israele 25
KZ - Kazakistan 23
DK - Danimarca 22
TT - Trinidad e Tobago 22
CR - Costa Rica 21
EE - Estonia 21
GR - Grecia 21
DZ - Algeria 20
BG - Bulgaria 19
NP - Nepal 19
TN - Tunisia 19
HN - Honduras 17
BO - Bolivia 16
AL - Albania 15
HU - Ungheria 15
ET - Etiopia 14
KG - Kirghizistan 14
LB - Libano 14
LV - Lettonia 14
UY - Uruguay 14
OM - Oman 13
PA - Panama 12
SV - El Salvador 12
PS - Palestinian Territory 11
SN - Senegal 11
TH - Thailandia 11
CY - Cipro 10
GT - Guatemala 10
NI - Nicaragua 10
BY - Bielorussia 9
DO - Repubblica Dominicana 9
EU - Europa 9
GE - Georgia 9
LK - Sri Lanka 9
MK - Macedonia 9
NO - Norvegia 9
QA - Qatar 9
RS - Serbia 8
TW - Taiwan 8
LA - Repubblica Popolare Democratica del Laos 7
NZ - Nuova Zelanda 7
PR - Porto Rico 7
Totale 74.866
Salva come PNG Salva come JPEG
Città #
Dallas 4.570
Southend 3.025
Dublin 2.958
Singapore 2.586
Ashburn 2.443
San Jose 2.074
Fairfield 2.071
Milan 1.548
Moscow 1.534
Santa Clara 1.525
Chandler 1.426
Hong Kong 1.220
Council Bluffs 1.164
Beijing 949
Woodbridge 883
Siena 821
Houston 795
Hefei 788
Seattle 786
Wilmington 699
Los Angeles 631
Cambridge 630
Jacksonville 593
Rome 586
New York 549
Seoul 530
Ho Chi Minh City 521
Helsinki 506
Munich 488
Princeton 473
Florence 418
Hanoi 409
Ann Arbor 405
Lauterbourg 377
Lastra a Signa 349
The Dalles 342
Johannesburg 322
São Paulo 205
Columbus 195
Buffalo 189
Chicago 186
Dong Ket 184
Boardman 183
Nanjing 178
Shanghai 168
San Diego 160
Orem 154
London 152
Tokyo 145
Dearborn 139
Bengaluru 137
San Mateo 128
Warsaw 124
Turku 123
Frankfurt am Main 121
Málaga 120
Redondo Beach 117
Phoenix 115
Figino 108
Fremont 102
Nuremberg 102
Da Nang 96
Lappeenranta 96
Abidjan 95
Atlanta 93
Montreal 92
Turin 91
Chennai 90
Brooklyn 89
Toronto 88
Naples 84
Düsseldorf 82
Abuja 77
Washington 77
Nanchang 74
Haiphong 73
Denver 71
Stockholm 71
Portsmouth 68
Brno 66
Bologna 65
Rio de Janeiro 64
Boston 61
Manchester 59
Miami 58
Vienna 58
Baghdad 57
San Francisco 57
Guangzhou 56
Menlo Park 55
Amsterdam 54
Catania 54
Tashkent 54
Poplar 53
Shenyang 52
Ottawa 51
Mexico City 49
Brasília 46
Changsha 46
Brussels 43
Totale 48.194
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.081
A first update on mapping the human genetic architecture of COVID-19 615
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 599
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 520
Genetic mechanisms of critical illness in COVID-19 463
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 450
Cytokine modulators in the treatment of sarcoidosis 422
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 401
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 400
An explainable model of host genetic interactions linked to COVID-19 severity 397
Pathogen-sugar interactions revealed by universal saturation transfer analysis 381
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 372
Antirheumatic agents in covid-19: is IL-6 the right target? 372
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 369
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 360
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 360
Colonizzazione e trapianto di polmone: il possibile ruolo dei colonizzanti multiresistenti sugli eventi infettivi in uno studio pilota osservazionale-retrospettivo 334
Mapping the human genetic architecture of COVID-19 334
Peripheral biomarkers' panel for severe COVID-19 patients 330
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 326
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 322
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 321
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 319
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 318
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 315
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 310
POS0871 diagnostic accuracy og power doppler ultrasonography for the diagnosis of idiopathic inflammmatory myopathies 309
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 309
Accuracy of power Doppler ultrasonography in the diagnosis and monitoring of idiopathic inflammatory myopathies 308
Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways 300
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 300
Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity 297
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 296
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 292
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 290
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 289
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 283
Exhaled nitric oxide in interstitial lung diseases 282
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 281
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 281
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 279
Gorham-Stout disease management during pregnancy 278
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? 276
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 276
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 274
Increased Risk of Atherosclerosis in Patients with Sarcoidosis 271
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1 270
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 270
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 270
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 270
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 268
Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis 266
Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases 261
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 261
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 260
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 260
Prognostic bioindicators in severe COVID-19 patients 260
Omalizumab treatment in Samter's triad: case series and review of the literature 257
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 257
Serial KL-6 measurements in COVID-19 patients 257
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 255
Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 253
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 253
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 253
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 252
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 251
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 251
Serum amyloid A in patients with idiopathic pulmonary fibrosis 251
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis 250
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 250
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 249
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 249
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 248
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 245
A functional proteomics approach to the comprehension of sarcoidosis 244
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 243
Chitotriosidase activity in patients with interstitial lung disesaes 243
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline 242
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 242
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 242
Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer 241
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 240
Strategies for Maximising Lung Utilisation in Donors After Brain and Cardiac Death: A Narrative Review 239
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 239
Pirfenidone in chronic lung allograft dysfunction: a single cohort study 239
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 239
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 238
NK and NKT-like cells in granulomatous and fibrotic lung diseases 237
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 237
Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19 236
The analysis of tryptase in serum of sarcoidosis patients 234
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 233
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 233
Chromosome 5 inversion in two siblings, one with Klinefelter syndrome and systemic sclerosis, the other with rheumatoid arthritis 232
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 232
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 232
Cor pulmonale: the role of traditional and advanced echocardiography in the acute and chronic settings 232
Analysis of carbonylated proteins in BAL of patients with diffuse lung diseases 231
Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent 231
Chitotriosidase: a sensitive biomarker of sarcoidosis 231
Totale 29.921
Salva come PNG Salva come JPEG
Categoria #
all - tutte 252.978
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 252.978
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.187 0 0 0 305 222 157 199 211 185 526 484 898
2022/20235.729 424 592 717 691 415 1.044 359 485 447 202 213 140
2023/20245.524 218 138 517 273 294 1.280 1.644 226 62 179 179 514
2024/202512.165 715 524 1.290 671 1.397 660 611 736 943 617 1.273 2.728
2025/202630.169 2.060 3.922 3.596 3.385 5.267 1.078 3.571 886 1.093 1.963 973 2.375
2026/20274.752 1.281 1.000 2.012 459 0 0 0 0 0 0 0 0
Totale 76.514